Please login to the form below

Not currently logged in
Email:
Password:

Acorda appoints new CFO

Michael Rodgers replaces David Lawrence who becomes chief business officer

Acorda has reshuffled its senior business leadership, with Michael Rodgers appointed chief financial officer replacing David Lawrence who becomes chief business officer.

Rodgers joins from BG Medicine where he also served as chief financial officer. During his time at BG he led the company's initial public offering and helped launch its first product.

His previous roles include chief financial officer of Indevus Pharmaceuticals, where he stayed for 10 years before the company was acquired by Endo Pharmaceuticals.

Rodgers' predecessor as Acorda's chief financial officer David Lawrence moves to the newly-created role of chief business officer, where he will be responsible for the company's technical operations, project management, IT and facilities.

“We've grown rapidly over the past several years, and our internal operations need to keep pace with the demands of the business,” said Lawrence.

“I'm excited to take on this new challenge at Acorda, overseeing and optimising development of our business operations and infrastructure.”

This growth is led by six therapies in clinical studies that address a range of disorders including post-stroke deficits, epilepsy, cerebral palsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain and heart failure. 

9th October 2013

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Six factors that drive a multiple sclerosis patient's choice of disease-modifying therapy
MS advocate Trishna Bharadia explains the numerous factors that lead patients to choose a disease-modifying therapy, including the important considerations healthcare professionals and pharma often forget....
Innovative approaches in the treatment of multiple sclerosis
Blue Latitude Health Senior Associate Consultant Will Frostick delves into the MS treatment landscape and explores some of the cutting-edge treatments on the horizon....
Mobilising the public to combat the antimicrobial resistance crisis
Antimicrobial resistance is one of the greatest threats to human health, according to the World Health Organisation. So why doesn’t the public seem bothered? BLH Account Executive Ford Stewart examines...

Infographics